Lupin Q1 FY27 revenue and profit rise year-on-year; VISUfarma acquisition completed

Lupin's board met on 6 August 2026 and approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. Statutory auditors Deloitte Haskins & Sells conducted a limited review and issued a conclusion that was not modified. The disclosure covers standalone and consolidated statements, segment information, and notes on exceptional items and an acquisition concluded during the quarter.

On a consolidated basis, both total revenue from operations and profit after tax were higher than in the year-earlier quarter, and the standalone figures also rose year-on-year. The current quarter carried no exceptional items, whereas the comparative March 2026 quarter did. The exact figures and their period-on-period comparisons appear in the key-numbers panel. Within the segments, pharmaceuticals accounts for the bulk of revenue, while the smaller 'others' segment continued to report a loss.

Per the filing, Lupin's subsidiary Nanomi B.V. concluded the acquisition of wholly owned subsidiary VISUfarma B.V., Netherlands, on 1 April 2026. Fair value of intangibles, deferred tax liability and goodwill were accounted for provisionally, based on an independent valuer's report, with acquisition-related costs booked under 'other expenses'. The consolidated entities now include several newly added VISUfarma group companies across the Netherlands, UK, Italy, Spain and France. The filing also recaps prior-year exceptional items relating to US antitrust litigation settlements and a settlement with Astellas over Mirabegron ER Tablets, none of which affected the current quarter's exceptional-items line.